First Ebola Prevention Drug Trial Launches in Congo

A promising new chapter in fighting Ebola began this week as the World Health Organization launched the first clinical trial of a drug that could prevent infection in people exposed to the virus.

The trial, called EBO-PEP, is testing an oral antiviral drug called obeldesivir in the Democratic Republic of Congo, where a deadly Bundibugyo Ebola outbreak has infected over 1,960 people and killed more than 700 since May. This marks the first time scientists have tested whether a drug can stop exposed people from getting sick.

The experimental medication, developed by pharmaceutical company Gilead Sciences, has already shown promise in lab studies against the wider family of viruses that cause hemorrhagic fevers. Now researchers are recruiting nearly 1,000 participants aged 12 and older who've had direct contact with confirmed cases within the past five days but aren't showing symptoms yet.

Each participant will take the pill and receive daily monitoring for 21 days, with a final checkup at 42 days. The trial is happening at centers in Bunia and Rwampara in Ituri province, where more than 90 percent of outbreak cases have occurred.

Unlike other Ebola strains, the Bundibugyo variety has no approved vaccines or treatments. That makes this prevention trial especially critical for protecting healthcare workers, family members, and others who've been exposed through close contact with infected people.

The Ripple Effect

This breakthrough matters beyond just one outbreak. If obeldesivir proves effective, it could become a game-changing tool for future Ebola responses worldwide, protecting vulnerable communities before infection takes hold.

WHO Director-General Tedros Adhanom Ghebreyesus captured the moment perfectly: "Every breakthrough begins with hope." If successful, this drug could mark a major step forward in stopping contacts from developing disease.

Scientists are also testing two other potential treatments for people already sick with Bundibugyo, including a monoclonal antibody and another antiviral drug called remdesivir. Those trials began in early July and could take months to produce definitive results.

The fact that multiple medical solutions are now being tested simultaneously represents unprecedented progress in tackling a rare but deadly disease that has long challenged global health experts.

For the first time, exposed individuals have a potential shield against Ebola infection, not just treatment after symptoms appear.